Dr. Phyllis Barkman Ferrell is an innovator, investor, and incubator for longevity. She is passionate about brain health and committed to creating a world that allows our global aging population and economies to thrive. After three decades as a life sciences executive at Eli Lilly & Company, Phyllis retired from the pharmaceutical business and is now working with for-profit and non-profit organizations to transform health systems around the world. Phyllis has a BA in Economics from DePauw University, an MBA from Stanford University, and a DrPH in Global Public Health from Indiana University. In 2021, she led the launch of the Davos Alzheimer's Collaborative for System Preparedness, a global multi-stakeholder partnership of organizations aimed at mobilizing the world against Alzheimer’s disease, with the specific focus of ensuring that health systems are prepared to embrace innovation and better care for our global aging population. Phyllis is also the Chief Impact Officer of the StartUp Health Alzheimer's Moonshot, a new global initiative that aims to break down silos and foster meaningful collaboration and entrepreneurial support between mission-aligned founders and champions. Phyllis is a current member of the World Dementia Council, an advisory board member of the Milken Institute Center for Future of Aging, the European Platform for Neurodegenerative Disease, the AD Data Initiative, the USC Clinical Trial Recruiting Laboratory, the Alzheimer's Drug Discovery Foundation, the HOSA Center for Future Health Professionals, and a member of the Forbes Business Council. Phyllis is passionate about Alzheimer’s advocacy and brain health so that other boys don’t have to grow up without their grandfathers’ presence as her sons did.